scholarly journals Rationale of Therapeutic Plasma Exchange as Rescue Immunomodulatory Treatment for MIS-C With Multiorgan Failure

2021 ◽  
Vol 40 (7) ◽  
pp. e259-e262
Author(s):  
Franco Díaz ◽  
Camila Cores ◽  
Omar Atenas ◽  
Nicolás Rodríguez ◽  
Raúl Bustos ◽  
...  
2018 ◽  
Vol 46 (1) ◽  
pp. 695-695
Author(s):  
Philip Keith ◽  
Lauren Eyadiel ◽  
Jeremy Hodges ◽  
Karen Sands ◽  
Jared Watkins

2013 ◽  
Vol 28 (6) ◽  
pp. 971-974 ◽  
Author(s):  
Vimal Master Sankar Raj ◽  
Amanda Alladin ◽  
Brent Pfeiffer ◽  
Chryso Katsoufis ◽  
Marissa Defreitas ◽  
...  

Author(s):  
Akingbola T. S. ◽  
Shonde-Adebola K. B. ◽  
Anyanwu-Yeiya C. C. ◽  
Ezekekwu C. A. ◽  
Adeoye O. A. ◽  
...  

BACKGROUND: Therapeutic Plasma Exchange (TPE) is an apheresis treatment in which the plasma component of blood is removed and replaced with supplemental fluids. It is an immunomodulatory treatment that has been reported to be a successful therapeutic procedure for the treatment of severely compromised patients with myasthenia gravis when given at short intervals. TPE is known to have a comparable efficacy to intravenous immunoglobulin (IVIG) in the treatments of patients with moderate to severe myasthenia crisis. METHODOLOGY: We report a case of a 47year old male patient with severe myasthenia crisis. He was managed using cobe spectra version 6.1 to carry out an automated TPE, with a suboptimal response and subsequent use of IVIG resulting in full recovery. This report highlights the possible factors that may hinder optimal response of a patient with Myasthenia crisis to TPE procedure in a poor resource setting. CONCLUSION: TPE is an essential immunomodulatory therapy in the management of acute myasthenia crisis whether given alone or in combination with immunosuppressive drugs. There can be a rebound overproduction of the offending autoantibodies in MG following TPE which can be cleared from circulation using immunosuppressive therapy.


Transfusion ◽  
2017 ◽  
Vol 58 (2) ◽  
pp. 470-479 ◽  
Author(s):  
James E. Louie ◽  
Caitlin J. Anderson ◽  
Katayoun Fayaz M. Fomani ◽  
Alonye Henry ◽  
Trevor Killeen ◽  
...  

Author(s):  
Gürkan Atay ◽  
Demet Demirkol

AbstractTherapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases. In this study, we aimed to assess the indications, efficacy, reliability, complications, and treatment response of pediatric patients for TPE. This retrospective study analyzed data from 39 patients aged from 0 to 18 years who underwent a total of 172 TPE sessions from January 2015 to April 2018 in a tertiary pediatric intensive care unit. Indications for TPE were, in order of frequency, macrophage activation syndrome (28.2%, n = 11), renal transplantation rejection (15.4%, n = 6), liver failure (15.4%, n = 6), Guillain–Barre's syndrome (15%, n = 6), hemolytic uremic syndrome (7.7%, n = 3), acute demyelinating disease (7.7%, n = 3), septic shock (5.1%, n = 2), and intoxication (5.1%, n = 2). No patient had any adverse event related to the TPE during the procedure. The TPE session was ended prematurely in one patient due to insufficient vascular access and lack of blood flow (2.6%). In the long term, thrombosis due to the indwelling central catheter occurred (5.1%, n = 2). TPE appears to be an effective first-stage or supplementary treatment in a variety of diseases, may be safely used in pediatric patients, and there are significant findings that its area of use will increase. In experienced hands and when assessed carefully, it appears that the rate of adverse reactions and vascular access problems may be low enough to be negligible.


2018 ◽  
Vol 20 (4) ◽  
pp. 394-403
Author(s):  
M. S. Vetsheva ◽  
◽  
K.E Loss . ◽  
O.L. Podkorytova ◽  
E.V. Lebedkov ◽  
...  

2004 ◽  
Vol 30 (3) ◽  
pp. 181-184 ◽  
Author(s):  
Önder Arslan ◽  
Mutlu Arat ◽  
Ibrahim Tek ◽  
Erol Ayyildiz ◽  
Osman Ilhan

Sign in / Sign up

Export Citation Format

Share Document